JP Morgan Maintains Overweight on Agilent Technologies, Raises Price Target to $190
JP Morgan analyst Casey Woodring maintains Agilent Technologies (NYSE:A) with a Overweight and raises the price target from $180 to $190.
Read original at benzingaStocks · News reference
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 27, 2026, 5:35 PM
- Checked
- Aug 27, 2026, 5:35 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
TD Cowen Maintains Buy on Agilent Technologies, Raises Price Target to $180
TD Cowen analyst Dan Brennan maintains Agilent Technologies (NYSE:A) with a Buy and raises the price target from $155 to $180.
Read original at benzingaLaboratory Informatics Market to Grow from USD 4.08 Billion in 2025 to USD 6.69 Billion by 2035, at a CAGR of 5.06% - SNS Insider
The global laboratory informatics market is projected to grow at a CAGR of 5.06% from 2025 to 2035, driven by increased data processing demands, regulatory compliance requirements, and adoption of cloud-native solutions and AI-driven analytics. North America leads with 42.55% market share, while Asia-Pacific is the fastest-growing region. Services and LIMS products dominate, with cloud delivery and electronic lab notebooks showing the strongest growth rates.
Read original at globenewswire-incBernstein Maintains Outperform on Agilent Technologies, Raises Price Target to $180
Bernstein analyst Eve Burstein maintains Agilent Technologies (NYSE:A) with a Outperform and raises the price target from $155 to $180.
Read original at benzingaAstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease
AstraZeneca & Amgen’s Tezspire achieves significant Phase 3 CROSSING trial results in eosinophilic esophagitis (EoE) treatment.
Read original at benzingaAstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial
Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52Efficacy in a third epithelial-driven inflammatory disease supports broad potential of
Read original at benzinga